Project Grant R43DK146368
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $250K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fayetteville, AR 72701, USA
Similar Awards
- The National Science Foundation awarded Micromedics Inc. $304,926 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to design and develop the mPancreas, a wearable biomimetically designed microfluidic bioartificial pancreas device. The research focuses on creating a compact implanted device that recreates the small-scale biological environment required for insulin-producing cells to survive and function outside the body. The device uses thin...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $1,046,335 to Well Cell Global LLC on August 11, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a randomized clinical trial examining the metabolic mechanisms underlying Physiologic Insulin Resensitization (PIR) in Type 2 Diabetes Mellitus. The recipient will enroll 40 subjects—20 receiving PIR and 20 receiving standard of care—over 12 months to evaluate how...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $275,275 to Integrated Medical Sensors Inc. on September 17, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a miniaturized and flexible continuous glucose monitoring platform. Integrated Medical Sensors will optimize the design of its electrochemical analyte sensing platform by expanding the use of flexible electronics to create a first-in-class band-aid...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Minnesota Healthsolutions Corporation $628,558 on September 12, 2025, to develop and evaluate an innovative dialysis cannulation needle designed to reduce accidental needle infiltration injury during hemodialysis. The award funds work under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which supports extramural biomedical research that improves understanding of disease...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services, awarded Silq Technologies Corporation $320,965 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Silq will develop a zwitterion-treated ureteral stent designed to reduce device-related complications in patients with ureteral obstructions. The work encompasses three aims: developing the zwitterion-treated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Persista Bio Inc. $287,250 on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop the manufacturing process for the cell capsule of the O2LINE implant system, an oxygenated cell encapsulation technology targeting Type 1 Diabetes treatment. The O2LINE system addresses limitations in current insulin pump therapy and donor-dependent islet...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Pupil Bio, Inc. $1,015,056 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an early detection test for Type 1 Diabetes using next-generation sequencing analysis of B cell-specific methylation patterns in cell-free DNA. Pupil Bio will refine marker selection to identify methylation patterns ultra-specific to pancreatic islet B cells, building...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded In Vivo Microsystems Technologies, LLC $3,067,867 on September 19, 2025, for a Phase 2 Small Business Innovation Research project under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). IVMT will conduct a Phase 2 multi-center in-vivo study of a near-infrared fluorescently-labeled peptide heterodimer targeting EGFR and ERBB2 for detection of biliary intra-epithelial neoplasia. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Panluminate Inc. $354,958 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate the PAN-EXM Renal Pathology Platform, an AI-enabled diagnostic system for podocytopathies including focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease. Panluminate will deliver three core products over the 30-month period...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $811,217 to the Trustees of Indiana University (Indiana University Indianapolis) on February 18, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop ultra-stable single-chain insulin analogs and glucose-responsive insulin analogs for type 1 diabetes management. The award funds research into signaling mechanisms that control insulin stability and glucose...